CAMBRIDGE, Mass., June 2, 2020 – Myeloid Therapeutics, a biotech company harnessing the innate immune system to eradicate cancer and other diseases, today announced a presentation at the Jefferies 2020 Virtual Healthcare Conference.
Chief Scientific Officer Daniel Getts, Ph.D., will give a company overview and provide an update on its lead oncology and COVID-19 programs on Wednesday, June 3, at 4 p.m. ET. A webcast of the event will be available at: http://wsw.com/webcast/jeff126/myth/.
About Myeloid Therapeutics
Myeloid Therapeutics is a biotechnology company focused on advancing its proprietary cell therapy platform, known as ATAKTM, which reprograms innate immune cells to eradicate disease. Led by world-renowned experts in oncology, immunology, cell therapy, synthetic biology, and virology, the company has built a platform cell manufacturing process that supports the rapid translation of the company’s lead assets, MT-101 for T cell Lymphoma and MT-202 for HER2 expressing solid tumors. Myeloid is collaborating with Duke University to advance its lead ATAKTM vaccine program, MT-201, a glioblastoma vaccine. The company is also leveraging its ATAK platform to develop MT-202, in partnership with Duke University, as a COVID-19 vaccine option for high-risk individuals, including older adults and healthcare workers. The company expects to initiate Phase 1 clinical trials for its lead programs later this year.
Myeloid Therapeutics was founded in 2019 by Ronald Vale, Ph.D., and Siddhartha Mukherjee, M.D., DPhil, and backed with financing led by Newpath Partners with Hatteras, 8VC and Alexandria Real Estate Equities participating.
SOURCE Myeloid Therapeutics, Inc.